Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Orphazyme A/S    ORPHA   DK0060910917

ORPHAZYME A/S

(ORPHA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Orphazyme A/S : Notice to convene Annual General Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2019 | 08:01am EDT

Orphazyme A/S
Company announcement                                                                                                                  

No. 06/2019                                                                                                                                        
Company Registration No. 32266355                                                                                                                                                                    

 

Copenhagen, Denmark, March 5, 2019Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Orphazyme A/S Annual General Meeting will be held on:

Wednesday, March 27, 2019 at 5:00 PM (CET)

at the Company’s address Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.

The notice to convene the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, is attached.

Additional information about the Annual General Meeting is available at Orphazyme A/S’ website,
http://phx.corporate-ir.net/phoenix.zhtml?c=254662&p=irol-agm.

 

For additional information, please contact

Orphazyme A/S
Anders Vadsholt, CFO                         +45 28 98 90 55

 

About Orphazyme A/S 
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com

Forward-looking statement
This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Attachments

  • 06-2019 Notice to convene Annual General Meeting
  • Notice to Convene AGM 2019
  • Appendix 1

© OMX, source OMX

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ORPHAZYME A/S
06/21CYTRX CORPORATION : Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Reg..
AQ
06/07ORPHAZYME A/S : to prepare for filing of arimoclomol in Europe for Niemann-Pick ..
AQ
05/31ORPHAZYME A/S : Major shareholder announcement
AQ
04/23ORPHAZYME A/S : Phase II/III trial in sporadic Inclusion Body Myositis fully enr..
AQ
04/17ORPHAZYME A/S : Major shareholder announcement
AQ
03/27ORPHAZYME A/S : Resolution passed at the Annual General Meeting
AQ
03/11ORPHAZYME A/S : to present at Cowen & Co Annual Health Care Conference
AQ
03/05ORPHAZYME A/S : Notice to convene Annual General Meeting
AQ
03/04ORPHAZYME A/S : Reporting of transactions in Orphazyme's shares made by persons ..
AQ
03/04REDEYE : Orphazyme - Summary of 2018, important year ahead
AQ
More news
Financials (DKK)
Sales 2019 -
EBIT 2019 -329 M
Net income 2019 -329 M
Finance 2019 94,3 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 0
EV / Sales 2020 87,6x
Capitalization 1 059 M
Chart ORPHAZYME A/S
Duration : Period :
Orphazyme A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORPHAZYME A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 117  DKK
Spread / Average Target 120%
EPS Revisions
Managers
NameTitle
Anders Mørkebjerg Hinsby Chief Executive Officer
Georges Gemayel Chairman
Anders Fink Vadsholt Chief Financial Officer
Thomas Kirkegaard Jensen Chief Scientific Officer
Thomas Blaettler Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ORPHAZYME A/S22.26%152
GILEAD SCIENCES10.92%80 909
VERTEX PHARMACEUTICALS11.02%42 680
REGENERON PHARMACEUTICALS-14.29%32 744
GENMAB12.51%10 857
SAREPTA THERAPEUTICS INC19.01%8 523